Achieve Life Sciences (NASDAQ:ACHV) Issues Quarterly Earnings Results

Achieve Life Sciences (NASDAQ:ACHV) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11, FiscalAI reports.

Here are the key takeaways from Achieve Life Sciences’ conference call:

• Achieve said its recent $180 million private placement, with up to $174 million more from milestone warrants, gives the company a strong capital base to pursue approval and launch plans.
• The company expects an FDA complete response letter tied to issues at a prior third-party manufacturer and plans to resubmit the NDA in Q4 2026 with Adare Pharma Solutions as the primary U.S. commercial supply partner.
• Management highlighted encouraging clinical and mechanistic data for cytisinicline, including selective receptor activity that may help explain its low nausea rates and strong efficacy in hard-to-treat patients who previously used varenicline or bupropion.
• Achieve is moving ahead with an independent commercial launch strategy and has added experienced leaders from Verona Pharma, including a new commercial SVP and sales leadership for the field force.
• The company reiterated plans to advance its vaping program, saying it hopes to initiate the ORCA-V2 phase III trial this year while continuing to work with FDA on timelines and trial design.

Achieve Life Sciences Stock Up 4.5%

Shares of ACHV traded up $0.25 during mid-day trading on Tuesday, hitting $5.84. 1,885,575 shares of the company’s stock were exchanged, compared to its average volume of 968,403. The company has a market cap of $310.86 million, a PE ratio of -4.47 and a beta of 2.25. Achieve Life Sciences has a 52 week low of $2.00 and a 52 week high of $6.15. The company has a 50-day simple moving average of $3.98 and a 200 day simple moving average of $4.44. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.39 and a quick ratio of 4.39.

Institutional Investors Weigh In On Achieve Life Sciences

Several large investors have recently made changes to their positions in the stock. Franklin Resources Inc. boosted its holdings in shares of Achieve Life Sciences by 18,747.4% in the 4th quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock valued at $21,715,000 after buying an additional 4,346,011 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Achieve Life Sciences by 14.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company’s stock valued at $7,755,000 after buying an additional 311,925 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Achieve Life Sciences by 472.3% in the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock valued at $6,755,000 after buying an additional 1,121,614 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Achieve Life Sciences in the 2nd quarter valued at approximately $2,652,000. Finally, Marshall Wace LLP boosted its holdings in shares of Achieve Life Sciences by 31.5% in the 4th quarter. Marshall Wace LLP now owns 1,019,281 shares of the biopharmaceutical company’s stock valued at $5,066,000 after buying an additional 244,428 shares during the last quarter. Institutional investors and hedge funds own 33.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ACHV shares. Weiss Ratings lowered shares of Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Achieve Life Sciences in a research note on Thursday, April 16th. Wall Street Zen raised shares of Achieve Life Sciences from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Canaccord Genuity Group set a $13.00 price target on shares of Achieve Life Sciences and gave the stock a “buy” rating in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $14.67.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.